IL251246A0 - Therapeutically active compounds and methods of use - Google Patents
Therapeutically active compounds and methods of useInfo
- Publication number
- IL251246A0 IL251246A0 IL251246A IL25124617A IL251246A0 IL 251246 A0 IL251246 A0 IL 251246A0 IL 251246 A IL251246 A IL 251246A IL 25124617 A IL25124617 A IL 25124617A IL 251246 A0 IL251246 A0 IL 251246A0
- Authority
- IL
- Israel
- Prior art keywords
- methods
- active compounds
- therapeutically active
- therapeutically
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462056996P | 2014-09-29 | 2014-09-29 | |
| PCT/US2015/052598 WO2016053850A1 (en) | 2014-09-29 | 2015-09-28 | Therapeutically active compounds and their methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL251246A0 true IL251246A0 (en) | 2017-05-29 |
Family
ID=54289133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL251246A IL251246A0 (en) | 2014-09-29 | 2017-03-17 | Therapeutically active compounds and methods of use |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US9694013B2 (OSRAM) |
| EP (1) | EP3200800A1 (OSRAM) |
| JP (2) | JP2017529382A (OSRAM) |
| KR (1) | KR20170057411A (OSRAM) |
| AU (1) | AU2015324158A1 (OSRAM) |
| CA (1) | CA2962943A1 (OSRAM) |
| IL (1) | IL251246A0 (OSRAM) |
| WO (1) | WO2016053850A1 (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI666208B (zh) * | 2013-08-02 | 2019-07-21 | 美商阿吉斯藥品有限公司 | 治療活性化合物及其使用方法（三） |
| WO2016053850A1 (en) * | 2014-09-29 | 2016-04-07 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| KR102628370B1 (ko) * | 2015-02-04 | 2024-01-24 | 르 라보레또레 쎄르비에르 | 치료적 활성 화합물 및 이들의 사용 방법 |
| US9751863B2 (en) | 2015-08-05 | 2017-09-05 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| SG10201912886XA (en) | 2015-10-15 | 2020-02-27 | Agios Pharmaceuticals Inc | Combination therapy for treating malignancies |
| SG10201912869WA (en) | 2015-10-15 | 2020-02-27 | Celgene Corp | Combination therapy for treating malignancies |
| MX380596B (es) | 2015-12-04 | 2025-03-12 | Agios Pharmaceuticals Inc | Compuesto para usarse en el tratamiento de neoplasias malignas. |
| EP3419593B1 (en) | 2016-02-26 | 2022-03-23 | Celgene Corporation | Enasidenib for use in the treatment of relapsed or refractory acute myeloid leukaemia |
| WO2018010142A1 (en) * | 2016-07-14 | 2018-01-18 | Shanghai Meton Pharmaceutical Co., Ltd | Iso-citrate dehydrogenase (idh) inhibitor |
| CN109715143A (zh) * | 2016-09-07 | 2019-05-03 | 细胞基因公司 | 片剂组合物 |
| ES2968376T3 (es) | 2017-05-05 | 2024-05-09 | Memorial Sloan Kettering Cancer Center | Métodos de tratamiento de neoplasia mieloproliferativa |
| WO2019078246A1 (ja) * | 2017-10-19 | 2019-04-25 | 一般社団法人ファルマバレープロジェクト支援機構 | Ｉｄｏ／ｔｄｏ阻害剤 |
| EP3716972A4 (en) * | 2017-11-29 | 2021-08-25 | The Rockefeller University | PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR THE TREATMENT OF AUTOIMMUNE DISEASES |
| WO2020092906A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof |
| WO2020092894A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol |
| WO2020092915A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Solid dispersions for treatment of cancer |
| WO2020239759A1 (en) * | 2019-05-27 | 2020-12-03 | Sandoz Ag | Amorphous enasidenib in a stabilized form |
| JP2023503842A (ja) * | 2019-11-14 | 2023-02-01 | セルジーン コーポレーション | がんを処置するための小児用製剤 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201403878QA (en) | 2012-01-06 | 2014-08-28 | Agios Pharmaceuticals Inc | Therapeutically active compounds and their methods of use |
| NZ715738A (en) | 2013-07-11 | 2021-06-25 | Agios Pharmaceuticals Inc | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer |
| US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| TWI666208B (zh) | 2013-08-02 | 2019-07-21 | 美商阿吉斯藥品有限公司 | 治療活性化合物及其使用方法（三） |
| WO2016053850A1 (en) | 2014-09-29 | 2016-04-07 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| KR102628370B1 (ko) | 2015-02-04 | 2024-01-24 | 르 라보레또레 쎄르비에르 | 치료적 활성 화합물 및 이들의 사용 방법 |
| US9751863B2 (en) | 2015-08-05 | 2017-09-05 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| SG10201912886XA (en) | 2015-10-15 | 2020-02-27 | Agios Pharmaceuticals Inc | Combination therapy for treating malignancies |
| MX380596B (es) | 2015-12-04 | 2025-03-12 | Agios Pharmaceuticals Inc | Compuesto para usarse en el tratamiento de neoplasias malignas. |
| EP3419593B1 (en) | 2016-02-26 | 2022-03-23 | Celgene Corporation | Enasidenib for use in the treatment of relapsed or refractory acute myeloid leukaemia |
-
2015
- 2015-09-28 WO PCT/US2015/052598 patent/WO2016053850A1/en not_active Ceased
- 2015-09-28 US US14/868,283 patent/US9694013B2/en active Active
- 2015-09-28 JP JP2017516874A patent/JP2017529382A/ja active Pending
- 2015-09-28 AU AU2015324158A patent/AU2015324158A1/en not_active Abandoned
- 2015-09-28 EP EP15778158.4A patent/EP3200800A1/en not_active Withdrawn
- 2015-09-28 KR KR1020177010757A patent/KR20170057411A/ko not_active Ceased
- 2015-09-28 CA CA2962943A patent/CA2962943A1/en not_active Abandoned
-
2017
- 2017-03-17 IL IL251246A patent/IL251246A0/en unknown
- 2017-06-02 US US15/612,984 patent/US9889137B2/en active Active
-
2018
- 2018-01-08 US US15/864,994 patent/US10105369B2/en active Active
-
2020
- 2020-05-13 JP JP2020084527A patent/JP2020147571A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017529382A (ja) | 2017-10-05 |
| US20170266193A1 (en) | 2017-09-21 |
| US20180125850A1 (en) | 2018-05-10 |
| US20160089374A1 (en) | 2016-03-31 |
| US9889137B2 (en) | 2018-02-13 |
| CA2962943A1 (en) | 2016-04-07 |
| KR20170057411A (ko) | 2017-05-24 |
| JP2020147571A (ja) | 2020-09-17 |
| WO2016053850A1 (en) | 2016-04-07 |
| US9694013B2 (en) | 2017-07-04 |
| AU2015324158A1 (en) | 2017-04-13 |
| EP3200800A1 (en) | 2017-08-09 |
| US10105369B2 (en) | 2018-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286316A (en) | New micro-dystrophins and related method of use | |
| IL270347B (en) | Therapeutically active compounds and methods of use | |
| IL251246A0 (en) | Therapeutically active compounds and methods of use | |
| IL253796A0 (en) | Therapeutically active compounds and methods of use | |
| IL250415B (en) | Antibodies against pd-l and methods of using them | |
| IL258768A (en) | Compounds interacting with glycans and methods of use | |
| ZA201600667B (en) | Therapeutically active compounds and their methods of use | |
| GB201403093D0 (en) | Therapeutic compounds and their use | |
| PL3548033T3 (pl) | Związki i sposoby ich stosowania | |
| ZA201605639B (en) | Hppd variants and methods of use | |
| GB201418350D0 (en) | Dispenser and methods of use thereof | |
| HUE061672T2 (hu) | Glikán-interakcióban lévõ vegyületek és felhasználási módszerek | |
| PT3089971T (pt) | Compostos e métodos de utilização | |
| ZA201606243B (en) | Hppd variants and methods of use | |
| IL265955A (en) | Therapeutic compounds and methods of using them | |
| IL254783B (en) | Combinations for deworming methods for using them | |
| SG11201605915WA (en) | Furo-3-carboxamide derivatives and methods of use | |
| ZA201802134B (en) | Therapeutic compounds and methods of use thereof | |
| ZA201606450B (en) | Compounds and their methods of use | |
| GB201403697D0 (en) | Compounds and methods of use | |
| ZA201700571B (en) | Therapeutically active compounds and their methods of use | |
| EP3212202A4 (en) | Use of therapeutic agents | |
| AU2014904330A0 (en) | Use of therapeutic agents | |
| GB201410387D0 (en) | Compounds and their therapeutic use | |
| GB201403496D0 (en) | Compounds and their therapeutic use |